Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 21, 2006; 12(19): 3114-3118
Published online May 21, 2006. doi: 10.3748/wjg.v12.i19.3114
Published online May 21, 2006. doi: 10.3748/wjg.v12.i19.3114
Table 1 Demographic Data of the patients
Group A(n = 11) | Group B(n = 18) | Group C(n = 7) | |
Age (mean±SD yr) | 46.6 ± 10.6 | 47.1 ± 7.8 | 53.6 ± 5.7 |
Gender (women/men) | 4/7 | 3/15 | 1/6 |
Immunosuppression regimen before switch | |||
Tacrolimus+steroids+MMF | 7 | 4 | 1 |
Tacrolimus+steroids | 4 | 14 | 6 |
Immunosuppression regimen after switch | |||
Sirolimus+tacrolimus | 8 | 13 | 5 |
Sirolimus+steroids+tacrolimus | 3 | 5 | 2 |
Table 2 Tumor status at the time of transplantation
Group A (n = 11) | Group B (n = 18) | Group C (n = 7) | |
Stage | |||
I | 0 | 0 | 4 |
II | 0 | 0 | 3 |
III | 4 | 9 | 0 |
IV | 7 | 9 | 0 |
Grade (WHO) | |||
I | 1 | 0 | 4 |
II | 6 | 10 | 3 |
III | 4 | 8 | 0 |
PVTT | |||
Yes | 6 | 6 | 0 |
No | 5 | 12 | 7 |
- Citation: Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 2006; 12(19): 3114-3118
- URL: https://www.wjgnet.com/1007-9327/full/v12/i19/3114.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i19.3114